Liora, a subsidiary of LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), Introduces New CEO, Brings Experience to Treating Tumors with Proton Therapy

• There are several types of technologies for treating tumors with proton therapy, such as pencil beam scanning, passive scattering, and others
• Linac for Image Guided Hadron Therapy, LiGHT system, is believed to offer a more affordable, compact, and efficient design, along with better treatment precision than traditional technologies
• The system complements LIXTE’s lead clinical candidate, LB-100, which is a small-molecule PP2A inhibitor which is designed to enhance the activity of immunotherapy and chemotherapy

Treating tumors with proton therapy is a highly advanced form of radiation that offers high precision, which minimizes radiation exposure for the tissue around the tumor. There are various types of technologies used for treating tumors with proton therapy, such as pencil beam scanning, passive scattering, and others.

Pencil beam scanning is when a narrow beam is used to essentially “paint” the tumor with radiation, layer by layer. On the other hand, passive scattering, which is an older technique, is when a narrow proton beam passes through scattering material to create a wider beam to match the size of the tumor.

However, Liora Technologies, a subsidiary of LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is bringing something new to the table when it comes to proton therapy with the Linac for Image Guided Hadron Therapy (“LiGHT”) System.

The LiGHT System is believed to provide meaningful advantages over conventional proton therapy platforms. Its compact footprint and modular architecture make it significantly smaller and more cost-effective than traditional systems, while also enabling faster deployment timelines. These attributes have the potential to expand access to advanced proton therapy by lowering infrastructure and installation barriers that have historically limited adoption.

In addition to its scalability benefits, the LiGHT system improves operational efficiency. Unlike many legacy proton systems that rely on mechanical degraders to adjust beam energy, a process that generates excess radiation and reduces efficiency, the LiGHT platform adjusts energy electronically. This approach minimizes radiation waste and allows energy levels to shift within milliseconds, enabling highly precise dose control tailored to each patient’s treatment plan.

This technology complements LIXTE’s main product and lead clinical candidate, LB-100. LB-100 is a small-molecule PP2A prohibitor that’s designed to enhance chemotherapy and immunotherapy. It has demonstrated a favorable safety profile in Phase 1 clinical trials and is supported by more than 25 studies.

LB-100 and the LiGHT System work well together, as the LiGHT System works to effectively destroy cancer cells, while the LB-100 helps to prevent these cancer cells from being able to repair themselves. LB-100 also makes cancer cells more vulnerable to the radiation from the LiGHT system, increasing how effective the treatment may be.

Recently, LIXTE also announced that it has named Sidney Braun as the new CEO for Liora to help lead the team. Braun is very experienced in the healthcare industry and brings more than two decades of strategic and operational advisory experience to the table.

He was also a big part of the creation of Liora and helped to facilitate the acquisition by LIXTE. Braun holds degrees in economics and business administration, is multilingual, and has worked for companies in North America, Europe, and Israel.

Speaking about the appointment of Braun, LIXTE CEO, Geordan Pursglove, said, “The appointment of Sidney Braun as CEO of Liora is in keeping with our plan to bring Liora’s LiGHT System technology to the forefront of modern cancer treatment and eventually enable LIXTE to pursue a recurring revenue model.”

He also added that “We welcome Sidney to the LIXTE family and are confident of the contributions he will make to our organization and to advancing and scaling an important technology in cancer treatment.”

About LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT)

LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical company that develops cancer therapies. But rather than introducing standalone treatments, it focuses on advancing a first-in-class approach to enhance the effectiveness of established therapies and address common challenges. The work centers on improving how both chemotherapy and immunotherapy perform in cancers that are difficult to treat.

For more information, visit the company website at https://lixte.com.

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at https://nnw.fm/LIXT

About NetworkNewsWire